Clinical Studies of Theranostic Uses of Antibodies or Antibody-Related Therapeutics Labeled with PET Radionuclides
| Target | Tracer name | Tracer structure | No. of (ongoing) clinical trials | Patient population | No. of centers |
| Tumor | |||||
| A33 | 124I-huA33 | mAb | 1 | CRC | 1 |
| CA6 | 64Cu-B-Fab | Fab fragment | 1 | Breast or ovarian cancer | 1 |
| CA9 | 124I-girentuximab | mAb | 5 | RCC | 16 |
| 89Zr-girentuximab | mAb | 2 | RCC | 3 | |
| CEA | 89Zr-AMG 211 | BiTE | 1 | Gastrointestinal adenocarcinoma | 2 |
| CD20 | 89Zr-ibritumomab tiuxetan | mAb | 1 | NHL | 1 |
| CD44 | 89Zr-RG7356 | mAb | 1 | CD44-positive solid tumor | 6 |
| EGFR (HER1) | 89Zr-cetuximab | mAb | 4 | CRC, HNSCC, stage IV cancer | 4 |
| 89Zr-panitumumab | mAb | 2 | CRC, NSCLC, sarcoma, urothelial carcinoma | 1 | |
| EphA2 | 89Zr-DS-8895a | mAb | 1 | EphA2-positive cancer | 1 |
| HER2 | 64Cu-trastuzumab | mAb | 7 | Breast or gastric cancer | 3 |
| 68Ga-HER2-Nanobody | Nanobody | 1 | Breast cancer | 1 | |
| 68Ga-trastuzumab-Fab | Fab fragment | 1 | Breast cancer | 1 | |
| 89Zr-trastuzumab | mAb | 7 | Breast cancer | 7 | |
| HER3 | 64Cu-patritumab | mAb | 1 | Solid tumors | 1 |
| 89Zr-GSK2849330 | mAb | 1 | HER3-positive solid tumors | 1 | |
| 89Zr-lumretuzumab | mAb | 1 | HER3-positive solid tumors | 12 | |
| MSLN | 89Zr-MMOT0530A | mAb | 1 | Ovarian or pancreatic cancer | 2 |
| PIGF | 89Zr-RO5323441 | mAb | 1 | GBM | 1 |
| PSCA | 124I-A11 | Minibody | 1 | Bladder, pancreatic, or prostate cancer | 1 |
| PSMA | 89Zr-J591 | mAb | 4 | GBM, prostate cancer | 2 |
| STEAP1 | 89Zr-MSTP2109A | mAb | 1 | Prostate cancer | 1 |
| Microenvironment | |||||
| PD-1 | 89Zr-pembrolizumab | mAb | 1 | NSCLC, melanoma | 2 |
| PD-L1 | 89Zr-atezolizumab | mAb | 1 | Bladder cancer, NSCLC, TNBC | 1 |
| TGFβ | 89Zr-fresolimumab | mAb | 1 | Glioma | 1 |
| VEGF-A | 89Zr-bevacizumab | mAb | 9 | Breast cancer, glioma, MM, NET, NSCLC, RCC | 3 |
CRC = colorectal carcinoma; CA6 = carbonic anhydrase 6; CA9 = carbonic anhydrase 9; NHL = non-Hodgkin lymphoma; EGFR = epidermal growth factor receptor; HER1 = human epidermal growth factor receptor 1; HNSCC = head and neck squamous cell carcinoma; EphA2 = ephrin receptor A2; HER3 = human epidermal growth factor receptor 3; MSLN = mesothelin; PIGF = placental growth factor; GBM = glioblastoma multiforme; PSCA = prostate stem cell antigen; PSMA = prostate-specific membrane antigen; STEAP1 = 6-transmembrane epithelial antigen of prostate family member 1; TNBC = triple-negative breast cancer; TGFβ = transforming growth factor β; MM = multiple myeloma; NET = neuroendocrine tumor.